公开(公告)号：WO2019213550A1

公开(公告)日：2019-11-07

申请号：PCT/US2019/030643

申请日：2019-05-03

Applicant: DUKE UNIVERSITY ,  THE JOHNS HOPKINS UNIVERSITY

Inventor： HE, You-Wen ,  SUN, Heqiang ,  AUGUST, Thomas ,  LIU, Jun ,  WEI, Yadong

IPC: A61K39/21 ,  A61P31/12 ,  A61K39/12

Abstract: Vaccine design, polycistronic vaccine constructs, compositions, and methods comprising nucleic acids (DNA, RNA), peptides, proteins and derivatives thereof, including cells and cell-lines, for enhanced antigen-specific vaccination.

公开(公告)号：WO2017087784A1

公开(公告)日：2017-05-26

申请号：PCT/US2016/062739

申请日：2016-11-18

Applicant: DUKE UNIVERSITY ,  HE, You-Wen ,  WANG, Yu

Inventor： HE, You-Wen ,  WANG, Yu

IPC: A01N63/00 ,  A61K38/20 ,  A61K38/21 ,  A61K39/00 ,  A61P35/00 ,  C07H21/02

CPC classification number: A61K33/24 ,  A61K31/555 ,  A61K38/00 ,  A61K45/06 ,  C07K14/54 ,  C07K14/705 ,  C07K16/2818 ,  C07K2319/75 ,  A61K2300/00

Abstract: Tumor infiltrating lymphocytes (TILs) are white blood cells that are actively recruited to the tumor site to mount an immune response against tumor growth and metastasis. The disclosure provides methods for treating cancer that comprise steps of isolating CD8+ T cells from a sample derived from a subject, expanding the CD8+ T cells in the presence of interleukin-10, and administering the expanded CD8+ T cells to the subject. Methods of treating cancer may be used in combination with inhibitors of the complement signaling pathway.

Abstract translation: 肿瘤浸润淋巴细胞（TIL）是积极招募到肿瘤部位的白血细胞，以产生针对肿瘤生长和转移的免疫应答。 本公开提供了用于治疗癌症的方法，所述方法包括以下步骤：从来自受试者的样品分离CD8 + T细胞，在白细胞介素-10存在下扩增CD8 + T细胞，并将扩增的CD8 + T细胞施用于受试者。 治疗癌症的方法可以与补体信号传导途径的抑制剂组合使用。

公开(公告)号：WO2017087768A1

公开(公告)日：2017-05-26

申请号：PCT/US2016/062717

申请日：2016-11-18

Applicant: DUKE UNIVERSITY ,  HE, You-Wen ,  WANG, Yu

Inventor： HE, You-Wen ,  WANG, Yu

IPC: A61K38/20 ,  A61K39/395 ,  A61P35/00 ,  C07K14/54 ,  C07K14/705 ,  C07K16/28

CPC classification number: A61K33/24 ,  A61K31/555 ,  A61K38/00 ,  A61K45/06 ,  C07K14/54 ,  C07K14/705 ,  C07K16/2818 ,  C07K2319/75 ,  A61K2300/00

Abstract: Disclosed are targeted interleukin-10 molecules that may be useful for treating cancer. Disclosed methods of treating cancer may be used in combination with inhibitors of the complement signaling pathway.

Abstract translation: 公开了可用于治疗癌症的靶向白细胞介素-10分子。 公开的治疗癌症的方法可以与补体信号传导途径的抑制剂组合使用。

公开(公告)号：WO2014093504A1

公开(公告)日：2014-06-19

申请号：PCT/US2013/074426

申请日：2013-12-11

Applicant: DUKE UNIVERSITY

Inventor： HE, You-Wen ,  XIAO, Bin ,  CHAO, Nelson J.

IPC: C12Q1/68 ,  C12N15/11

CPC classification number: C12Q1/6883 ,  C12Q2600/118 ,  C12Q2600/158

Abstract: The present disclosure provides miRNA biomarkers useful for determining the risk of, prognosis of, and/or diagnosis of conditions such as GVHD in a subject.

Abstract translation: 本公开提供了可用于确定受试者中诸如GVHD之类的病症的风险，预后和/或诊断的miRNA生物标志物。

公开(公告)号：WO2019204730A1

公开(公告)日：2019-10-24

申请号：PCT/US2019/028326

申请日：2019-04-19

Applicant: DUKE UNIVERSITY

Inventor： HE, You-Wen ,  WANG, Yu ,  CHAO, Nelson

IPC: C12N15/11 ,  C12N15/113 ,  C12Q1/68

Abstract: Provided are compositions and methods for donor selection and prognosis of acute graft-versus-host disease. Provided is a method, which comprises obtaining a first biological sample from a first subject at risk of GVHD; detecting a level of miR-142-3p in the sample; and determining a risk of, prognosis of, or diagnosis of GVHD in the first subject. Provided also is a method for selecting a stem cell transplant donor, which comprises obtaining a first biological sample from a first subject and a second biological sample from a second subject, detecting a level of miR-142-3p in the first biological sample and the second biological sample; determining a ratio of the level of miR-142-3p in the second biological sample to the level of miR-142-3p in the first biological sample; determining the likelihood of the first subject will develop GVHD based on the ratio; and selecting a transplant donor based on the ratio.